Chemical Component Summary

Name TOBRAMYCIN
Identifiers (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxy-oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol
Formula C18 H37 N5 O9
Molecular Weight 467.514  g/mol
Type NON-POLYMER
Isomeric SMILES NC[C@H]1O[C@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3O[C@H](CO)[C@@H](O)[C@H](N)[C@H]3O)[C@H]2O)[C@H](N)C[C@@H]1O
InChI InChI=1S/C18H37N5O9/c19-3-9-8(25)2-7(22)17(29-9)31-15-5(20)1-6(21)16(14(15)28)32-18-13(27)11(23)12(26)10(4-24)30-18/h5-18,24-28H,1-4,19-23H2/t5-,6+,7+,8-,9+,10+,11-,12+,13+,14-,15+,16-,17+,18+/m0/s1
InChIKey NLVFBUXFDBBNBW-PBSUHMDJSA-N

Chemical Details

Formal Charge 0
Atom Count 69
Chiral Atom Count 14
Chiral Atoms C11 C12 C13 C21 C23 C32 C33 C41 C42 C43 C51 C52 C53 C62
Bond Count 71
Aromatic Bond Count 0
Leaving Atoms n/a

Drug Info: DrugBank

DrugBank ID DB00684   (Stereoisomeric match)
Name Tobramycin
Groups
  • approved
  • investigational
Description An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the pseudomonas species. It is a 10% component of the antibiotic complex, nebramycin, produced by the same species. [PubChem]
Synonyms
  • 3'-Deoxykanamycin b
  • Nebramycin 6
  • Nebramycin factir 6
  • Nebramycin-Faktor 6
  • O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Salts
  • 3'-Deoxykanamycin b
  • Nebramycin 6
  • Nebramycin factir 6
  • Nebramycin-Faktor 6
  • O-3-Amino-3-deoxy-alpha-D-glucopyranosyl-(1-4)-O-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribohexopyranosyl-(1-4))-2-deoxy-D-streptamine
Brand Names
  • Aj-tobramycin
  • Apo-tobramycin
  • Bethkis
  • Jamp-tobramycin
  • Kitabis Pak
Affected Organism Enteric bacteria and other eubacteria
Indication For the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.
Pharmacology Tobramycin, an aminoglycoside antibiotic obtained from cultures of <i>Streptomyces tenebrarius</i>, is used in combination with other antibiotics to treat urinary tract infections, gynecologic infections, peritonitis, endocarditis, pneumonia, bacteremia and sepsis, respiratory infections including those associated with cystic fibrosis, osteomyelitis, and diabetic foot and other soft-tissue infections. It acts primarily by disrupting protein synthesis, leading to altered cell membrane permeability, progressive disruption of the cell envelope, and eventual cell death. Tobramycin has in vitro activity against a wide range of gram-negative organisms including <em>Pseudomonas aeruginosa</em>.
Mechanism of action Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin.
Route of administration
  • inhalation
  • intramuscular; intravenous
  • intravenous
  • ophthalmic
  • oral
Categories
  • Anti-Bacterial Agents
  • Aminoglycosides
ATC-Code
  • J01GB01
  • S01AA12
AHFS-Code
  • 08:12.02
  • 52:04.04
CAS number 32986-56-4

Drug Targets

Name Sequence Search Pharmacological Action Actions
30S ribosomal protein S12 MATVNQLVRKPRARKVAKSNVPALEACPQKRGVCTRVYTTTPKKPNSALR... yes inhibitor
... unknown inhibitor
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682